Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022160228 - MUCUS ADHESION DRUG DELIVERY

Publication Number WO/2022/160228
Publication Date 04.08.2022
International Application No. PCT/CN2021/074312
International Filing Date 29.01.2021
Chapter 2 Demand Filed 10.02.2022
IPC
A61K 47/30 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 9/20 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
A61K 9/22 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
CPC
A61K 47/61
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
61the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 9/146
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
146with organic macromolecular compounds
A61K 9/284
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
28Dragees; Coated pills or tablets ; , e.g. with film or compression coating
2806Coating materials
2833Organic macromolecular compounds
284obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
Applicants
  • SUN, Yimin [CA]/[CN]
Inventors
  • SUN, Yimin
Agents
  • BEIJING GAOWO LAW FIRM
Priority Data
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) MUCUS ADHESION DRUG DELIVERY
(FR) ADMINISTRATION DE MÉDICAMENT PAR ADHÉSION AU MUCUS
Abstract
(EN) It relates to a mucus adhesion drug delivery technology. The technology involves the preparation of materials consisting of mucus adhesive excipient polymer chemically bonded with drug molecules and delivery of the materials with fast disintegration tablet with enteric coating to intestine. The bonding between the excipient polymer and the drug molecules is either ionic bonds, covalent bonds, or metal coordination bonds. The test of the mucus adhesion drug delivery technology was carried out using a dog model. The test data indicated successful retaining of drug molecules on the intestine mucus resulting in not only dramatic extension of drug release time, but also great improvement in the bioavailability of the API.
(FR) L'invention concerne une technologie d'administration de médicament par adhésion au mucus. La technologie implique la préparation de matériaux constitués d'un polymère d'excipient adhésif de mucus lié chimiquement à des molécules de médicament et l'administration des matériaux à l'intestin sous forme d'un comprimé à désintégration rapide comprenant un revêtement gastro-résistant. La liaison entre le polymère d'excipient et les molécules de médicament présente soit des liaisons ioniques, des liaisons covalentes ou des liaisons de coordination métalliques. L'essai de la technologie d'administration de médicament par adhésion au mucus a été réalisé à l'aide d'un modèle de chien. Les résultats d'essai indiquent la rétention réussie de molécules de médicament sur le mucus intestinal, ce qui entraîne non seulement une extension spectaculaire du temps de libération de médicament, mais également une amélioration considérable de la biodisponibilité de l'API.
Latest bibliographic data on file with the International Bureau